Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma

Francis J. Giles, Julie Marie Vose, Kim Anh Do, Marcella M. Johnson, Taghi Manshouri, Robert G Bociek, Philip Jay Bierman, Susan M. O'Brien, Hagop M. Kantarjian, James Olen Armitage, Maher Albitar

Research output: Contribution to journalArticle

59 Scopus citations


Vascular endothelial growth factor (VEGF), basic-fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and angiogenin are important angiogenic factors. In 65 patients with non-Hodgkin's lymphoma (NHL), pre-treatment VEGF, bFGF, and HGF levels were significantly elevated compared to normal individuals, while angiogenin levels were significantly subnormal. In 37 patients with Hodgkin's disease, pre-treatment levels of VEGF and HGF were significantly elevated, bFGF levels were normal, and angiogenin levels were significantly subnormal. In patients with NHL, post-therapy levels of angiogenin were independently predictive of survival. Both pre-therapy and post-therapy VEGF levels were independently predictive of survival in patients with HD.

Original languageEnglish (US)
Pages (from-to)595-604
Number of pages10
JournalLeukemia Research
Issue number6
StatePublished - Jun 1 2004



  • Angiogenin
  • HGF
  • Hodgkin's
  • Lymphoma
  • Prognosis
  • Survival
  • VEGF
  • bFGF

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this